EPGL Medical develops smart treatment devices for physicians

12 August 2013 (Last Updated August 12th, 2013 18:30)

US medical device manufacturer EPGL Medical has developed smart treatment devices that enhance situational awareness during operations, reducing risk to patients.

US medical device manufacturer EPGL Medical has developed smart treatment devices that enhance situational awareness during operations, reducing risk to patients.

The three devices are the MEMS epidural needle device, MEMS nerve ablation device and the MEMS trigger point needle device.

The epidural smart needle is designed for procedures that involve injections into the epidural area. Physicians generally use either air or saline to identify the epidural area but need to be careful, especially while threading the needle between vertebras into the epidural space. Puncturing the layer close to the epidural space which contains cerebrospinal fluid could create severe complications for the patient.

TopSpin micron movement precision technology with advanced sensors gives doctors better awareness while carrying out this procudure.

The MEMS nerve ablation device also employs TopSpin precision technology to eliminate the ability of a nerve to send pain signals to the brain, which in turn provides temporary relief to patients undergoing surgery.

The MEMS trigger point needle device is intended for the treatment of myofascial trigger points. Using MEMS technology sensors through a TopSpin platform, the device accurately identifies the dimensions and perimeter of the myofascial trigger points that need to be injected. Doctors require a more accurate needling device for treatment of these points with dry, saline or local anesthetic injections.

EPGL biomedical engineer David T Markus noted that the firm is amassing advanced device technologies at a rapid pace and will make its mark with development of smarter medical devices.

"We have the advantage in advanced MEMS technology and this is the field that will revolutionise medicine in the next several years," Markus added.

The company plans for 510k clearance from the US Food and Drug Administration in order to market the products.